Superworth

Bicycle Therapeutics EPS BCYC

Diluted earnings per share by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2026
−$2.73
Latest quarter, Q2 FY26
−$0.72
Fiscal year 2025
−$3.16

Bicycle Therapeutics' earnings per share was −$2.73 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.72.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$3.16n/a
FY2024−$2.88n/a
FY2023−$5.13n/a
FY2022−$3.80n/a
FY2021−$2.68n/a
FY2020−$2.65n/a
FY2019−$9.98n/a
FY2018−$49.15n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.72n/a−$2.73
Q1 FY26−$0.87n/a−$3.15
Q4 FY25−$0.29n/a−$3.16
Q3 FY25−$0.85n/a−$3.62
Q2 FY25−$1.14n/a−$3.51
Q1 FY25−$0.88n/a−$3.14
Q4 FY24−$0.75n/a−$2.88
Q3 FY24−$0.74n/a−$3.29
Q2 FY24−$0.77n/a−$3.81
Q1 FY24−$0.62n/a−$4.45
Q4 FY23−$1.16n/a−$5.13
Q3 FY23−$1.26n/a−$4.98

Against its peers

Companies in Drug Manufacturers - General nearest Bicycle Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
BCYCBicycle Therapeutics−$2.73
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
ABUSArbutus Biopharma$0.78
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
Peer median$0.78

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Bicycle Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.